Published in Mol Imaging on February 01, 2011
Rapid tumoritropic accumulation of systemically injected plateloid particles and their biodistribution. J Control Release (2011) 1.72
Multistage vector (MSV) therapeutics. J Control Release (2015) 0.84
Porous silicon advances in drug delivery and immunotherapy. Curr Opin Pharmacol (2013) 0.81
Characterization of Free and Porous Silicon-Encapsulated Superparamagnetic Iron Oxide Nanoparticles as Platforms for the Development of Theranostic Vaccines. Med Sci (Basel) (2014) 0.80
Preparation, characterization, and cellular associations of silicon logic-embedded vectors. Methods Enzymol (2012) 0.75
Reduced Cationic Nanoparticle Cytotoxicity Based on Serum Masking of Surface Potential. J Biomed Nanotechnol (2016) 0.75
High resolution two-dimensional electrophoresis of proteins. J Biol Chem (1975) 133.45
Statistical significance for genomewide studies. Proc Natl Acad Sci U S A (2003) 88.64
Openings between defective endothelial cells explain tumor vessel leakiness. Am J Pathol (2000) 5.94
Nanoparticle size and surface properties determine the protein corona with possible implications for biological impacts. Proc Natl Acad Sci U S A (2008) 5.76
ProFound: an expert system for protein identification using mass spectrometric peptide mapping information. Anal Chem (2000) 3.42
Size and shape effects in the biodistribution of intravascularly injected particles. J Control Release (2009) 3.08
What the cell "sees" in bionanoscience. J Am Chem Soc (2010) 3.07
Cationic charge determines the distribution of liposomes between the vascular and extravascular compartments of tumors. Cancer Res (2002) 2.09
Frontiers in cancer nanomedicine: directing mass transport through biological barriers. Trends Biotechnol (2010) 1.90
Cationic liposomes target angiogenic endothelial cells in tumors and chronic inflammation in mice. J Clin Invest (1998) 1.72
Tailored porous silicon microparticles: fabrication and properties. Chemphyschem (2010) 1.71
The association of silicon microparticles with endothelial cells in drug delivery to the vasculature. Biomaterials (2009) 1.63
Effect of the surface charge of liposomes on their uptake by angiogenic tumor vessels. Int J Cancer (2003) 1.38
Antibiological barrier nanovector technology for cancer applications. Expert Opin Drug Deliv (2007) 1.36
Polymorphic forms of human apolipoprotein[a]: inheritance and relationship of their molecular weights to plasma levels of lipoprotein[a]. J Lipid Res (1990) 1.33
Cellular association and assembly of a multistage delivery system. Small (2010) 1.32
Identification of a new structural variant of human apolipoprotein E, E2(Lys146 leads to Gln), in a type III hyperlipoproteinemic subject with the E3/2 phenotype. J Clin Invest (1983) 1.15
Impact of hydrogel nanoparticle size and functionalization on in vivo behavior for lung imaging and therapeutics. Mol Pharm (2009) 1.12
A comparison of silver stain and SYPRO Ruby Protein Gel Stain with respect to protein detection in two-dimensional gels and identification by peptide mass profiling. Electrophoresis (2000) 1.11
The receptor binding domain of apolipoprotein E, linked to a model class A amphipathic helix, enhances internalization and degradation of LDL by fibroblasts. Biochemistry (2000) 1.10
The transport of nanoparticles in blood vessels: the effect of vessel permeability and blood rheology. Ann Biomed Eng (2008) 1.07
Complement C1q-target proteins recognition is inhibited by electric moment effectors. J Mol Recognit (2007) 0.90
Influence of surface charge on adsorption of fibrinogen and/or albumin on a rotating disc electrode of platinum and carbon. Biomaterials (1990) 0.88
The surface charge of apolipoproteins, phospholipid liposomes, and human very low density lipoproteins. J Biol Chem (1983) 0.78
The Fc-recognizing, collagen-like C1q molecule is a putative type II membrane protein of macrophages. Behring Inst Mitt (1993) 0.78
Development of novel fibrinogen nanoparticles by two-step co-acervation method. Int J Biol Macromol (2010) 0.78
Mesoporous silicon particles as a multistage delivery system for imaging and therapeutic applications. Nat Nanotechnol (2008) 3.78
Quantum dots spectrally distinguish multiple species within the tumor milieu in vivo. Nat Med (2005) 3.19
Intravascular delivery of particulate systems: does geometry really matter? Pharm Res (2008) 3.13
Clinical proteomics: written in blood. Nature (2003) 2.81
Sustained small interfering RNA delivery by mesoporous silicon particles. Cancer Res (2010) 2.80
Nanomedicine--challenge and perspectives. Angew Chem Int Ed Engl (2009) 2.74
Nanotechnologies for biomolecular detection and medical diagnostics. Curr Opin Chem Biol (2006) 2.74
Seven challenges for nanomedicine. Nat Nanotechnol (2008) 2.59
Geometrical confinement of gadolinium-based contrast agents in nanoporous particles enhances T1 contrast. Nat Nanotechnol (2010) 2.17
Micelles from lipid derivatives of water-soluble polymers as delivery systems for poorly soluble drugs. Adv Drug Deliv Rev (2004) 2.13
Intracellular delivery of large molecules and small particles by cell-penetrating proteins and peptides. Adv Drug Deliv Rev (2004) 2.12
Cationic charge determines the distribution of liposomes between the vascular and extravascular compartments of tumors. Cancer Res (2002) 2.09
Functionalized micellar systems for cancer targeted drug delivery. Pharm Res (2007) 1.90
Matrix metalloprotease 2-responsive multifunctional liposomal nanocarrier for enhanced tumor targeting. ACS Nano (2012) 1.86
Synthetic nanoparticles functionalized with biomimetic leukocyte membranes possess cell-like functions. Nat Nanotechnol (2012) 1.85
Tumor-targeted liposomes: doxorubicin-loaded long-circulating liposomes modified with anti-cancer antibody. J Control Release (2004) 1.80
Design maps for nanoparticles targeting the diseased microvasculature. Biomaterials (2007) 1.72
Rapid tumoritropic accumulation of systemically injected plateloid particles and their biodistribution. J Control Release (2011) 1.72
Tailored porous silicon microparticles: fabrication and properties. Chemphyschem (2010) 1.71
Cell-penetrating peptides: breaking through to the other side. Trends Mol Med (2012) 1.68
Shaping nano-/micro-particles for enhanced vascular interaction in laminar flows. Nanotechnology (2009) 1.63
The association of silicon microparticles with endothelial cells in drug delivery to the vasculature. Biomaterials (2009) 1.63
Src activation by β-adrenoreceptors is a key switch for tumour metastasis. Nat Commun (2013) 1.62
Therapeutic Targeting of ATP7B in Ovarian Carcinoma. Clin Cancer Res (2009) 1.61
Polyethylene glycol-diacyllipid micelles demonstrate increased acculumation in subcutaneous tumors in mice. Pharm Res (2002) 1.60
What does physics have to do with cancer? Nat Rev Cancer (2011) 1.59
Lipid modified triblock PAMAM-based nanocarriers for siRNA drug co-delivery. Biomaterials (2012) 1.59
Liposome clearance in mice: the effect of a separate and combined presence of surface charge and polymer coating. Int J Pharm (2002) 1.58
Morphologic instability and cancer invasion. Clin Cancer Res (2005) 1.55
Nanogeometry: beyond drug delivery. Nat Nanotechnol (2008) 1.54
Prediction of drug response in breast cancer using integrative experimental/computational modeling. Cancer Res (2009) 1.53
Mesenchymal stem cells promote mammosphere formation and decrease E-cadherin in normal and malignant breast cells. PLoS One (2010) 1.49
Predicting drug pharmacokinetics and effect in vascularized tumors using computer simulation. J Math Biol (2008) 1.48
Osmotic pressure beyond concentration restrictions. J Phys Chem B (2007) 1.46
Multistage nanovectors: from concept to novel imaging contrast agents and therapeutics. Acc Chem Res (2011) 1.45
Biotechnology apprenticeship for secondary-level students: teaching advanced cell culture techniques for research. Cell Biol Educ (2002) 1.45
Hesperetin impairs glucose uptake and inhibits proliferation of breast cancer cells. Cell Biochem Funct (2012) 1.44
Design, synthesis, and characterization of pH-sensitive PEG-PE conjugates for stimuli-sensitive pharmaceutical nanocarriers: the effect of substitutes at the hydrazone linkage on the ph stability of PEG-PE conjugates. Bioconjug Chem (2007) 1.43
T helper type 1 lymphocytes drive inflammation in human atherosclerotic lesions. Proc Natl Acad Sci U S A (2003) 1.37
Antibiological barrier nanovector technology for cancer applications. Expert Opin Drug Deliv (2007) 1.36
Integrated intravital microscopy and mathematical modeling to optimize nanotherapeutics delivery to tumors. AIP Adv (2012) 1.35
Mitotic trafficking of silicon microparticles. Nanoscale (2009) 1.35
Tumor-targeted nanomedicines: enhanced antitumor efficacy in vivo of doxorubicin-loaded, long-circulating liposomes modified with cancer-specific monoclonal antibody. Clin Cancer Res (2009) 1.35
Discoidal Porous Silicon Particles: Fabrication and Biodistribution in Breast Cancer Bearing Mice. Adv Funct Mater (2012) 1.35
A physical sciences network characterization of non-tumorigenic and metastatic cells. Sci Rep (2013) 1.33
Cellular association and assembly of a multistage delivery system. Small (2010) 1.32
Biodegradable porous silicon barcode nanowires with defined geometry. Adv Funct Mater (2010) 1.31
Tailoring the degradation kinetics of mesoporous silicon structures through PEGylation. J Biomed Mater Res A (2010) 1.31
Mathematical modeling of cancer progression and response to chemotherapy. Expert Rev Anticancer Ther (2006) 1.30
Multiparameter computational modeling of tumor invasion. Cancer Res (2009) 1.28
Enabling individualized therapy through nanotechnology. Pharmacol Res (2010) 1.28
Enhanced transfection of tumor cells in vivo using "Smart" pH-sensitive TAT-modified pegylated liposomes. J Drug Target (2007) 1.27
Nanomedicine in cancer therapy: innovative trends and prospects. Cancer Sci (2011) 1.27
Transport properties of pancreatic cancer describe gemcitabine delivery and response. J Clin Invest (2014) 1.26
The preferential targeting of the diseased microvasculature by disk-like particles. Biomaterials (2012) 1.25
Unc119, a novel activator of Lck/Fyn, is essential for T cell activation. J Exp Med (2004) 1.25
Multifunctional PEGylated 2C5-immunoliposomes containing pH-sensitive bonds and TAT peptide for enhanced tumor cell internalization and cytotoxicity. J Control Release (2011) 1.25
Interstitial stress and fluid pressure within a growing tumor. Ann Biomed Eng (2003) 1.25
Multi-stage delivery nano-particle systems for therapeutic applications. Biochim Biophys Acta (2010) 1.23
Self-assembling micelle-like nanoparticles based on phospholipid-polyethyleneimine conjugates for systemic gene delivery. J Control Release (2008) 1.22
Emerging applications of nanomedicine for the diagnosis and treatment of cardiovascular diseases. Trends Pharmacol Sci (2010) 1.22
Enhanced binding and killing of target tumor cells by drug-loaded liposomes modified with tumor-specific phage fusion coat protein. Nanomedicine (Lond) (2010) 1.21
Enhancing chemotherapy response with sustained EphA2 silencing using multistage vector delivery. Clin Cancer Res (2013) 1.21
Organelle-targeted nanocarriers: specific delivery of liposomal ceramide to mitochondria enhances its cytotoxicity in vitro and in vivo. Nano Lett (2008) 1.19
Logic-embedded vectors for intracellular partitioning, endosomal escape, and exocytosis of nanoparticles. Small (2010) 1.19
Radiofrequency thermal ablation sharply increases intratumoral liposomal doxorubicin accumulation and tumor coagulation. Cancer Res (2003) 1.19
Identification of thioaptamer ligand against E-selectin: potential application for inflamed vasculature targeting. PLoS One (2010) 1.19
Host S-nitrosylation inhibits clostridial small molecule-activated glucosylating toxins. Nat Med (2011) 1.19
Increased accumulation of PEG-PE micelles in the area of experimental myocardial infarction in rabbits. J Control Release (2004) 1.19
Liposomes targeted by fusion phage proteins. Nanomedicine (2008) 1.19
MK2 controls the level of negative feedback in the NF-kappaB pathway and is essential for vascular permeability and airway inflammation. J Exp Med (2007) 1.18
Polyethylene glycol-phosphatidylethanolamine conjugate (PEG-PE)-based mixed micelles: some properties, loading with paclitaxel, and modulation of P-glycoprotein-mediated efflux. Int J Pharm (2006) 1.17
Paclitaxel-loaded polymeric micelles modified with MCF-7 cell-specific phage protein: enhanced binding to target cancer cells and increased cytotoxicity. Mol Pharm (2010) 1.17
Enhanced accumulation of long-circulating liposomes modified with the nucleosome-specific monoclonal antibody 2C5 in various tumours in mice: gamma-imaging studies. Eur J Nucl Med Mol Imaging (2006) 1.17
Discovery proteomics and nonparametric modeling pipeline in the development of a candidate biomarker panel for dengue hemorrhagic fever. Clin Transl Sci (2012) 1.17
Cooperative, nanoparticle-enabled thermal therapy of breast cancer. Adv Healthc Mater (2011) 1.16
Quantitative mechanics of endothelial phagocytosis of silicon microparticles. Cytometry A (2009) 1.16
Tailoring of the nanotexture of mesoporous silica films and their functionalized derivatives for selectively harvesting low molecular weight protein. ACS Nano (2010) 1.16
Design of bio-mimetic particles with enhanced vascular interaction. J Biomech (2009) 1.15
Intracellular trafficking of silicon particles and logic-embedded vectors. Nanoscale (2010) 1.15
Nanopreparations to overcome multidrug resistance in cancer. Adv Drug Deliv Rev (2013) 1.14
Enhanced cytotoxicity of monoclonal anticancer antibody 2C5-modified doxorubicin-loaded PEGylated liposomes against various tumor cell lines. Eur J Pharm Sci (2007) 1.14
P-glycoprotein silencing with siRNA delivered by DOPE-modified PEI overcomes doxorubicin resistance in breast cancer cells. Nanomedicine (Lond) (2012) 1.14
Design of multifunctional non-viral gene vectors to overcome physiological barriers: dilemmas and strategies. Int J Pharm (2011) 1.13
Laparoscopic treatment of splenic artery aneurysms. J Vasc Surg (2009) 1.13
Thiol-reactive dyes for fluorescence labeling of proteomic samples. Electrophoresis (2003) 1.13
E-selectin-targeted porous silicon particle for nanoparticle delivery to the bone marrow. Adv Mater (2011) 1.12
siRNA-containing liposomes modified with polyarginine effectively silence the targeted gene. J Control Release (2006) 1.12
Polymeric micelles for delivery of poorly soluble drugs: preparation and anticancer activity in vitro of paclitaxel incorporated into mixed micelles based on poly(ethylene glycol)-lipid conjugate and positively charged lipids. J Drug Target (2005) 1.12
Reversal of multidrug resistance by co-delivery of tariquidar (XR9576) and paclitaxel using long-circulating liposomes. Int J Pharm (2011) 1.12